COVID-19 Impact on Global Oncology Drugs Market By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancers); By Type (Chemotherapy, Targeted Therapy, Immunotherapy and Hormonal Therapy) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030
COVID-19 Impact on Global Oncology Drugs Market By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancers); By Type (Chemotherapy, Targeted Therapy, Immunotherapy and Hormonal Therapy) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030
*Please Note: The report will be delivered in 4-5 business days upon order confirmation*
- 1. Executive Summary
- 2. Oncology Drugs Market
- 2.1. Product Overview
- 2.2. Market Definition
- 2.3. Segmentation
- 2.4. Assumptions and Acronyms
- 3. Research Methodology
- 3.1. Research Objectives
- 3.2. Primary Research
- 3.3. Secondary Research
- 3.4. Forecast Model
- 3.5. Market Size Estimation
- 4. Average Pricing Analysis
- 5. Market Dynamics
- 5.1. Growth Drivers
- 5.2. Restraints
- 5.3. Opportunity
- 5.4. Trends
- 6. Correlation & Regression Analysis
- 6.1. Correlation Matrix
- 6.2. Regression Matrix
- 7. Recent Development, Policies & Regulatory Landscape
- 8. Risk Analysis
- 8.1. Demand Risk Analysis
- 8.2. Supply Risk Analysis
- 9. Oncology Drugs Market Analysis
- 9.1. Porters Five Forces
- 9.1.1. Threat of New Entrants
- 9.1.2. Bargaining Power of Suppliers
- 9.1.3. Threat of Substitutes
- 9.1.4. Rivalry
- 9.2. PEST Analysis
- 9.2.1. Political
- 9.2.2. Economic
- 9.2.3. Social
- 9.2.4. Technological
- 10. Oncology Drugs Market
- 10.1. Market Size & forecast, 2019A-2030F
- 10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 10.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 11. Oncology Drugs Market: Market Segmentation
- 11.1. By Regions
- 11.1.1. North America:(U.S. and Canada)
- 11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
- 11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
- 11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
- 11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 11.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
- 11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12. Oncology Drugs Market: Market Segmentation
- 12.1. By disease indication: Market Share (2020-2030F)
- 12.1.1. Lung Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.2. Stomach Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.3. Colorectal Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.4. Breast Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.5. Prostate Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.6. Liver Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.7. Esophagus Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.8. Cervical Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.9. Kidney Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.10. Bladder Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.1.11. Other Cancers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.2. By type : Market Share (2020-2030F)
- 12.2.1. Chemotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.2.2. Targeted Therapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.2.3. Immunotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 12.2.4. Hormonal Therapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 13. Company Profile
- 13.1. Bayer AG
- 13.1.1. Company Overview
- 13.1.2. Company Total Revenue (Financials)
- 13.1.3. Market Potential
- 13.1.4. Global Presence
- 13.1.5. Key Performance Indicators
- 13.1.6. SWOT Analysis
- 13.1.7. Product Launch
- 13.2. Genentech, Inc.
- 13.3. Novartis AG
- 13.4. Pfizer Inc.
- 13.5. Bristol-Myers Squibb Company
- 13.6. GlaxoSmithKline plc.
- 13.7. Eli Lilly and Company
- 13.8. AstraZeneca
- 13.9. Sanofi
- 13.10. Other prominent players
- Consultant Recommendation
- **The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook